Novel diagnostic and prognostic biomarkers in biliary tract cancer

Bibliography

• West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006;94:1751-8
   PubMed Web of Science ®Google Scholar
• Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-7
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-20
   PubMed Web of Science ®Google Scholar
• Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96
   PubMed Web of Science ®Google Scholar
• Khan SA, Miras A, Pelling M, et al. Cholangiocarcinoma and its management. Gut 2007;56:1755-6
   PubMed Web of Science ®Google Scholar
• Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(Suppl 6):VI1-9
   PubMedGoogle Scholar
• Saengsawang P, Promthet S, Bradshaw P. Infection with Opisthorchis viverrini and Use of Praziquantel among a Working-age Population in Northeast Thailand. Asian Pac J Cancer Prev 2013;14:2963-6
   PubMed Web of Science ®Google Scholar
• Fleming KA, Boberg KM, Glaumann H, et al. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001;34:360-5
   PubMed Web of Science ®Google Scholar
• Lewis JT, Talwalkar JA, Rosen CB, et al. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010;34:27-34
   PubMed Web of Science ®Google Scholar
• Enjoji M, Nakamuta M, Nawata H. Oncogenes in tumors of gallbladder and biliary tract. Fukuoka Igaku Zasshi 2004;95:31-5
   PubMedGoogle Scholar
• Klump B, Hsieh CJ, Dette S, et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res 2003;9:1773-8
   PubMed Web of Science ®Google Scholar
• Morales CP, Burdick JS, Saboorian MH, et al. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc 1998;48:402-5
   PubMed Web of Science ®Google Scholar
• Saluja SS, Sharma R, Pal S, et al. Differentiation between benign and malignant hilar obstructions using labaratory and radiological investigations: a prospective study. HPB (Oxford) 2007;9:373-82
   PubMedGoogle Scholar
• Fernandez- Esparrach G GA, Sanchez M, Pagés M, et al. Comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the diagnosis of pancreatobiliary diseases: a prospective study. Am J Gastroenterol 2007;102:1632-9
   PubMed Web of Science ®Google Scholar
• Sai JK, Kubokawa SM, Watanabe S, et al. Early detection of extrhepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest Endosc 2009;70:29-36
   PubMed Web of Science ®Google Scholar
• de Bellis M, Sherman S, Fofel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). Gastrointest Endosc 2002;56:720-30
   PubMed Web of Science ®Google Scholar
• Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214-19
   PubMed Web of Science ®Google Scholar
• Harewood GC, Baron TH, Stadheim LM, et al. Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 2004;99:1464-9
   PubMed Web of Science ®Google Scholar
• Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreobiliary strictures. Gasroenterology 2006;131:1064-72
   PubMed Web of Science ®Google Scholar
• Mohamadnejad M, DeWitt JM, Sherman S. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest Endosc 2011;73(1):71-8
   PubMed Web of Science ®Google Scholar
• Tischendorf JJ, Krüger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholanditis. Endoscopy 2006;38:665-9
   PubMed Web of Science ®Google Scholar
• Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with video). Gastrointest Endosc 2011;74:804-14
   Google Scholar
• Hoffman A, Kiesslich R, Bittinger F, et al. Methylene blue-aided cholangioscopy in patients with biliary strictures: feasibility and outcome analysis. Endoscopy 2008;40:563-71
   PubMed Web of Science ®Google Scholar
• Itoi T, Sofuni A, Itokawa F, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 2007;66(4):730-6
   PubMed Web of Science ®Google Scholar
• Lu XL, Itoi T, Kubota K. Cholangioscopy by using narrow-band imaging and transpapillary radiotherapy for mucin-producing bile duct tumour. Clin Gastroenterol Hepatol 2009;7:e34-5
   PubMedGoogle Scholar
• Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73. discussion 473-5
   PubMed Web of Science ®Google Scholar
• Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol 2009;25:238-9
   PubMed Web of Science ®Google Scholar
• Matull WR, Khan SA, Pereira SP. Re: impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2007;99:407; author reply 407-8
   PubMed Web of Science ®Google Scholar
• Anderson CD, Pinson CW, Berlin J, et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004;9:43-57
   PubMed Web of Science ®Google Scholar
• Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14
   PubMed Web of Science ®Google Scholar
• Reddy SB, Patel T. Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2006;8:30-7
   PubMedGoogle Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81
   PubMed Web of Science ®Google Scholar
• Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004;24:139-54
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27
   PubMed Web of Science ®Google Scholar
• Bonney GK, Craven RA, Prasad R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008;9:149-58
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6
   PubMed Web of Science ®Google Scholar
• Ventrucci M, Pozzato P, Cipolla A, et al. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 2009;41:357-63
   PubMedGoogle Scholar
• Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-7
   PubMed Web of Science ®Google Scholar
• Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology (Williston Park) 1995;9:19-24. discussion 24, 27, 30
   PubMedGoogle Scholar
• Sinakos E, Saenger AK, Keach J. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011;9:434-9. e1
   PubMed Web of Science ®Google Scholar
• Hotakainen K, Tanner P, Alfthan H. Comparison of three immunoassays for CA 19-9. Clin Chim Acta 2009;400:123-7
   PubMed Web of Science ®Google Scholar
• Koopmann J, Thuluvath PJ, Zahurak ML, et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004;101:1609-15
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006;6:42-51
   Google Scholar
• LaRusso NF, Shneider BL, Black D. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;4:746-64
   Google Scholar
• Goydos JS, Brumfield AM, Frezza E, et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998;227:398-404
   PubMed Web of Science ®Google Scholar
• Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007;102:2164-70
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Thong-ngam D, Theamboonlers A, et al. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 2004;51:15-19
   PubMed Web of Science ®Google Scholar
• Sandanayake NS, Sinclair J, Andreola F, et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011;105:1370-8
   PubMed Web of Science ®Google Scholar
• Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007;247:301-8
   PubMed Web of Science ®Google Scholar
• Wongkham S, Sheehan JK, Boonla C, et al. Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Lett 2003;195:93-9
   PubMed Web of Science ®Google Scholar
• Matull WR, Andreola F, Loh A, et al. MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer 2008;98:1675-81
   PubMed Web of Science ®Google Scholar
• Boonla C, Wongkham S, Sheehan JK, et al. Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 2003;98:1438-43
   PubMed Web of Science ®Google Scholar
• Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep 2009;22:649-57
   PubMed Web of Science ®Google Scholar
• Yi Y, Li B, Wang Z, et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 2009;14:480-5
   PubMed Web of Science ®Google Scholar
• Mizuguchi S, Nishiyama N, Iwata T, et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer 2007;58:369-75
   PubMed Web of Science ®Google Scholar
• Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008;15:583-9
   PubMed Web of Science ®Google Scholar
• Kashihara T, Ohki A, Kobayashi T, et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol 1998;33:447-53
   PubMed Web of Science ®Google Scholar
• Chapman MH, Sandanayake NS, Andreola F, et al. Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol 2011;1:6-12
   PubMedGoogle Scholar
• Lempinen M, Isoniemi H, Mäkisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007;47:677-83
   PubMed Web of Science ®Google Scholar
• Watanabe H, Enjoji M, Nakashima M, et al. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J Hepatol 2003;39:559-63
   PubMed Web of Science ®Google Scholar
• Enjoji M, Yamaguchi K, Nakamuta M, et al. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig Liver Dis 2004;36:622-7
   PubMedGoogle Scholar
• Enjoji M, Nakamuta M, Yamaguchi K, et al. RCAS1, a useful serum marker to predict the recurrence of cancer: two cases of cholangiocarcinoma and pancreatic cancer. Dig Dis Sci 2004;49:1654-6
   PubMed Web of Science ®Google Scholar
• Shi RY, Yang XR, Shen QJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer 2013;119:993-1003
   PubMed Web of Science ®Google Scholar
• Tolek A, Wongkham C, Proungvitaya S, et al. Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood) 2012;237:1142-9
   PubMed Web of Science ®Google Scholar
• Liu L, Wang J, Liu B, et al. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem 2008;104:745-55
   PubMed Web of Science ®Google Scholar
• Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 2007;147:451-9
   PubMed Web of Science ®Google Scholar
• Li YG, Zhang N. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis 2009;41:605-8
   PubMedGoogle Scholar
• Jamnongkan W, Techasen A, Thanan R, et al. Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. Tumour Biol 2013;34:695-704
   PubMed Web of Science ®Google Scholar
• Huang Q, Liu L, Lui CH, et al. Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis. Asian Pac J Cancer Prev 2012;13:5161-5
   PubMed Web of Science ®Google Scholar
• Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006;169:877-88
   PubMed Web of Science ®Google Scholar
• Chen CY, Tsai WL, Wu HC, et al. Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis. Clin Chim Acta 2008;390:82-9
   PubMed Web of Science ®Google Scholar
• Ayaru L, Stoeber K, Webster GJ, et al. Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer 2008;98:1548-54
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin XZ, Tsao HC, et al. The value of biliary fibronectin for diagnosis of cholangiocarcinoma. Hepatogastroenterology 2003;50(52):924-7
   PubMed Web of Science ®Google Scholar
• Shen J, Wang W, Wu J, et al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS ONE 2012;7(10):e47476
   PubMed Web of Science ®Google Scholar
• Dhar DK, Olde Damink SW, Brindley JH, et al. Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer. Cancer 2013;119:575-85
   PubMed Web of Science ®Google Scholar
• Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008;68(22):9184-93
   PubMed Web of Science ®Google Scholar
• Coufal M, Invernizzi P, Gaudio E, et al. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer 2010;126:2112-22
   PubMed Web of Science ®Google Scholar
• Huang L, Frampton G, Rao A, et al. Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest 2012;92:1451-60
   PubMed Web of Science ®Google Scholar
• Frampton G, Invernizzi P, Bernuzzi F, et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012;61:268-77
   PubMed Web of Science ®Google Scholar
• Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2012;62(1):122-30
   PubMed Web of Science ®Google Scholar
• Vasilieva LE, Papadhimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012;11(4):349-59
   PubMed Web of Science ®Google Scholar
• Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-72
   PubMed Web of Science ®Google Scholar
• Bergquist A, Tribukait B, Glaumann H, et al. Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000;33:873-7
   PubMed Web of Science ®Google Scholar
• Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010;51:174-80
   PubMed Web of Science ®Google Scholar
• Lindberg B, Enochsson L, Tribukait B, et al. Diagnostic and prognostic implications of DNA ploidy and S-phase evaluation in the assessment of malignancy in biliary strictures. Endoscopy 2006;38:561-5
   PubMed Web of Science ®Google Scholar
• American Society for Gastrointestinal Endoscopy (ASGE) Standards of Practice Committee. Anderson MA, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc 2013;77:167-74
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Andersson R, Svensson M, et al. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer 2013; doi: 10.1002/ijc.28256
   PubMed Web of Science ®Google Scholar
• Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 2009;45:33-47
   PubMed Web of Science ®Google Scholar
• Wise C, Pilanthananond M, Perry BF, et al. Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol 2008;14:2986-9
   PubMed Web of Science ®Google Scholar
• Boonjaraspinyo S, Boonmars T, Wu Z, et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 2012;33:1785-802
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Tornillo L, Zlobec I, et al. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 2008;130:780-6
   PubMed Web of Science ®Google Scholar
• Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60
   PubMed Web of Science ®Google Scholar
• DeHaan RD, Kipp BR, Smyrk TC, et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol 2007;38:491-9
   PubMed Web of Science ®Google Scholar
• Uhm KO, Park YN, Lee JY, et al. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet 2005;157:37-41
   PubMed Web of Science ®Google Scholar
• Ryu HS, Chung JH, Lee K, et al. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma. Hum Pathol 2012;43:2360-70
   PubMed Web of Science ®Google Scholar
• Lee HJ, Chung JY, Hewitt SM, et al. HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Arch 461:521-30
   PubMed Web of Science ®Google Scholar
• Nutthasirikul N, Limpaiboon T, Leelayuwat C, et al. Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol 2013;42:1181-8
   PubMed Web of Science ®Google Scholar
• Koo SH, Ihm CH, Kwon KC, et al. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2001;130:22-8
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Okita K, Harada T, et al. Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer 2001;91:570-7
   PubMed Web of Science ®Google Scholar
• Andresen K, Boberg KM, Vedeld HM, et al. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics 2012;7:1249-57
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89
   PubMed Web of Science ®Google Scholar
• Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008;27:378-86
   PubMed Web of Science ®Google Scholar
• Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010;51:881-90
   PubMed Web of Science ®Google Scholar
• Zhong XY, Yu JH, Zhang WG, et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 2012;493:44-51
   PubMed Web of Science ®Google Scholar
• Kemper JK. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta 2011;1812:842-50
   PubMed Web of Science ®Google Scholar
• Teodoro JS, Rolo AP, Palmeira CM. Hepatic FXR: key regulator of whole-body energy metabolism. Trends Endocrinol Metab 2011;22:458-66
   PubMed Web of Science ®Google Scholar
• Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 2012;143:246-56. e8
   PubMed Web of Science ®Google Scholar
• He Q, Cai L, Shuai L, et al. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 2013;52:286-96
   PubMed Web of Science ®Google Scholar
• Razumilava N, Bronk SF, Smoot RL, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 2012;55:465-75
   PubMed Web of Science ®Google Scholar
• Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs. World J Gastroenterol 2007;13:6465-9
   PubMed Web of Science ®Google Scholar
• Mott JL, Kobayashi S, Bronk SF, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-40
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29
   PubMed Web of Science ®Google Scholar
• Murugaesu N, Chew SK, Swanton C. Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol 182:1962-71
   PubMed Web of Science ®Google Scholar